Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).

MedStar author(s):
Citation: International Journal of Hyperthermia. :1-35, 2017 Mar 08PMID: 28540827Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2017ISSN:
  • 0265-6736
Name of journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupAbstract: AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from PM from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma.CONCLUSION: CRS and HIPEC appear to be safe and effective in patients with peritoneal metastases from unusual cancer sites of origin especially from rare ovarian carcinomas, PM from neuroendocrine tumors. The respective roles of CRS and HIPEC remain unclear and should be evaluated.PATIENTS AND METHODS: A questionnaire concerning patients treated with CRS plus HIPEC for PM arising from unusual cancer sites of origin was sent to all centers that routinely performed HIPEC, through the Peritoneal Surface Oncology Group International and the RENAPE network.RESULTS: Between Sept 1990 and June 2016, 850 procedures for unusual cases were performed in 781 patients, in 53 centers worldwide. Nearly two-thirds of the procedures were performed for three indications: rare ovarian carcinoma (n=224), sarcoma (n=189) and neuroendocrine tumors (n=127). The median PCI was 12 [0-39]. Grade III-IV postoperative complications occurred in 272 patients (41%). Nineteen patients (2.9%) died postoperatively. After a median follow-up of 46 months, median overall survival (OS) was 39 months [33.18-44.05]. 5-year OS rates were respectively 38.7%, For the 3 main indications, 5-year OS was significantly greater in patients with PM from rare ovarian carcinoma (57.7%), than that of patients with PM from neuroendocrine tumors (39.9%), and from sarcoma (29.3%) (p<0.0001).All authors: Bartlett DL, BIG-RENAPE Working Groups, Gelli M, Glehen O, Goere D, Levine EA, On behalf the PSOGI, Passot G, Sugarbaker PHFiscal year: FY2017Digital Object Identifier: Date added to catalog: 2017-06-14
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28540827 Available 28540827

AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from PM from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma.

CONCLUSION: CRS and HIPEC appear to be safe and effective in patients with peritoneal metastases from unusual cancer sites of origin especially from rare ovarian carcinomas, PM from neuroendocrine tumors. The respective roles of CRS and HIPEC remain unclear and should be evaluated.

PATIENTS AND METHODS: A questionnaire concerning patients treated with CRS plus HIPEC for PM arising from unusual cancer sites of origin was sent to all centers that routinely performed HIPEC, through the Peritoneal Surface Oncology Group International and the RENAPE network.

RESULTS: Between Sept 1990 and June 2016, 850 procedures for unusual cases were performed in 781 patients, in 53 centers worldwide. Nearly two-thirds of the procedures were performed for three indications: rare ovarian carcinoma (n=224), sarcoma (n=189) and neuroendocrine tumors (n=127). The median PCI was 12 [0-39]. Grade III-IV postoperative complications occurred in 272 patients (41%). Nineteen patients (2.9%) died postoperatively. After a median follow-up of 46 months, median overall survival (OS) was 39 months [33.18-44.05]. 5-year OS rates were respectively 38.7%, For the 3 main indications, 5-year OS was significantly greater in patients with PM from rare ovarian carcinoma (57.7%), than that of patients with PM from neuroendocrine tumors (39.9%), and from sarcoma (29.3%) (p<0.0001).

English

Powered by Koha